Effect of Pitavastatin on Amelioration for Renal Function in Patients with Chronic Kidney Disease

Effect of Pitavastatin on Amelioration for Renal Function in Patients with Chronic Kidney Disease - effect of PitavaSTatin on Amelioration for Renal function in patients with Chronic Kidney Disease (P-STAR-CKD)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001600

Enrollment

Registered

2009-01-20

Start date

2009-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypercholesterolemia patients evaluated inulin clearance with chronic kidney disease (stage 3)

Interventions

Pitavastatin 1 mg or 2 mg daily for a period of 6 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Patients of CKD stage 3 in stable* phase. *Stable: Patients whose creatine levels do not change more than 25% for 1 year. (2)Hypercholesterolemia patients or patients with serum LDL-C level of 120 mg/dL or more and required a cholesterol lowering agent. (3)Patients who are over 20 years old and less than 80 years old during observation periods. (4)Patients who were assessed GFR by inulin clearance within 3 months.

Exclusion criteria

Exclusion criteria: (1)Patients whose creatine levels change more than 25% in past 1 year. (2)Patients who are planed to change drugs for CKD. (3)Known hypersensitivity or history of clinically significant adverse reactions to Livalo. (4)Patients with serious hepatopathy or biliary obstruction. (5)Patients who are being treated with cyclosporine. (6)Pregnant, possibly pregnant, or lactating. (7)Patients who do not accept informed consent. (8)Patients who are judged unsuitable for this study by the doctor in charge of that patients.

Design outcomes

Primary

Measure	Time frame
Amount of change in inulin clearance	—

Secondary

Measure	Time frame
1)Comparison of a percent and amount change in inulin clearance and eGFR among baseline matched CKD stage3 patients who is under medical care in Nagoya University Hospital without statins prescription 2)A percent change in inulin clearance 3)A percent and amount of change in following factors 1.Serum lipid profile (TC, LDL-C, HDL-C, TG) 2.The laboratory parameters (AST, ALT, gamma-GTP, CK, and the other) 3.The laboratory parameters(RBC, WBC, Ht, and the other) 4.The special laboratory parameters (hs-CRP, 8-OHdG, alpha1 globulin, beta2 globulin, creatine) 5.Urinary protein (Urinary albumin)	—

Measure

Time frame

1)Comparison of a percent and amount change in inulin clearance and eGFR among baseline matched CKD stage3 patients who is under medical care in Nagoya University Hospital without statins prescription 2)A percent change in inulin clearance 3)A percent and amount of change in following factors 1.Serum lipid profile (TC, LDL-C, HDL-C, TG) 2.The laboratory parameters (AST, ALT, gamma-GTP, CK, and the other) 3.The laboratory parameters(RBC, WBC, Ht, and the other) 4.The special laboratory parameters (hs-CRP, 8-OHdG, alpha1 globulin, beta2 globulin, creatine) 5.Urinary protein (Urinary albumin)

—

Countries

Japan

Contacts

Public ContactYasuda Yoshinari

Nagoya University, Graduate School of Medicine Department of Nephrology

yyasuda@med.nagoya-u.ac.jp052-741-2111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026